| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| cytarabine | Injection, solution | 100 mg | Current | Limited Availability | Unexpected increase in consumer demand | 20/12/2024 |
| topiramate | Tablet, film coated | 25 mg | Resolved | Available | Manufacturing | 20/12/2024 |
| topiramate | Tablet, film coated | 100 mg | Current | Unavailable | Manufacturing | 20/12/2024 |
| topiramate | Tablet, film coated | 200 mg | Current | Unavailable | Manufacturing | 20/12/2024 |
| heparin sodium | Injection, solution | 5000 IU/mL | Current | Limited Availability | Unexpected increase in consumer demand | 20/12/2024 |
| fentanyl | Drug delivery system, transdermal | 16.8 mg | Current | Limited Availability | Manufacturing | 20/12/2024 |
| olanzapine | Tablet, orally disintegrating | 20 mg | Current | Limited Availability | Manufacturing | 20/12/2024 |
| levetiracetam | Tablet, film coated | 250 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 20/12/2024 |
| doxorubicin hydrochloride | Injection, concentrated | 2 mg/mL | Current | Limited Availability | Manufacturing | 20/12/2024 |
| trandolapril | Capsule, hard | 1 mg | Current | Limited Availability | Manufacturing | 20/12/2024 |
| olmesartan medoxomil | Tablet, film coated | 40 mg | Current | Unavailable | Manufacturing | 20/12/2024 |
| simvastatin | Tablet, film coated | 40 mg | Resolved | Available | Manufacturing | 20/12/2024 |
| codeine phosphate hemihydrate~ibuprofen | Tablet, film coated | 12.8 mg~200 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 20/12/2024 |
| voriconazole | Injection, powder for | 200 mg | Current | Unavailable | Manufacturing | 20/12/2024 |
| tadalafil | Tablet, film coated | 20 mg | Current | Limited Availability | Manufacturing | 20/12/2024 |
| dosulepin (dothiepin) hydrochloride | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 20/12/2024 |
| dasatinib | Tablet, film coated | 20 mg | Anticipated | Available | Unexpected increase in consumer demand | 20/12/2024 |
| fenofibrate | Tablet | 145 mg | Anticipated | Available | Manufacturing | 20/12/2024 |
| teriflunomide | Tablet, film coated | 14 mg | Current | Unavailable | Manufacturing | 20/12/2024 |
| latanoprost~timolol maleate | Eye Drops, solution | .05 mg/mL~6.83 mg/mL | Current | Unavailable | Manufacturing | 20/12/2024 |
| hydrochlorothiazide~olmesartan medoxomil~amlodipine besilate | Tablet, film coated | 25 mg~40 mg~6.95 mg | Resolved | Available | Manufacturing | 20/12/2024 |
| gentamicin sulfate | Injection, solution | 135.6 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 20/12/2024 |
| sodium amidotrizoate~amidotrizoate meglumine | Injection, solution | 40 mg/mL~260 mg/mL | Current | Unavailable | Manufacturing | 20/12/2024 |
| fluorouracil | Injection, solution | 50 mg/mL | Current | Limited Availability | Manufacturing | 20/12/2024 |
| oxycodone hydrochloride | Oral Liquid, solution | 1 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 20/12/2024 |
| methylphenidate hydrochloride | Capsule, modified release | 40 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 20/12/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 27 mg | Current | Limited Availability | Manufacturing | 19/12/2024 |
| tazobactam sodium~piperacillin sodium | Injection, powder for | .54 g~4.2 g | Discontinued | Unavailable | Unexpected increase in consumer demand | 19/12/2024 |
| fentanyl | Drug delivery system, transdermal | 12.6 mg | Anticipated | Available | Manufacturing | 19/12/2024 |
| midazolam | Injection, solution | 5 mg | Current | Limited Availability | Manufacturing | 19/12/2024 |
| diazepam | Tablet, uncoated | 2 mg | Resolved | Available | Manufacturing | 19/12/2024 |
| azithromycin | Injection, powder for | 500 mg | Current | Unavailable | Commercial Changes / Commercial viability | 19/12/2024 |
| trandolapril | Capsule, hard | .5 mg | Current | Unavailable | Manufacturing | 19/12/2024 |
| trandolapril | Capsule, hard | 2 mg | Current | Unavailable | Manufacturing | 19/12/2024 |
| trandolapril | Capsule, hard | 4 mg | Current | Unavailable | Manufacturing | 19/12/2024 |
| quetiapine fumarate | Tablet, film coated | 28.78 mg | Current | Unavailable | Manufacturing | 19/12/2024 |
| tobramycin | Injection, solution | 40 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 19/12/2024 |
| emtricitabine~tenofovir disoproxil maleate | Tablet, film coated | 200 mg~300 mg | Current | Unavailable | Manufacturing | 19/12/2024 |
| cinacalcet hydrochloride | Tablet | 99.191 mg | Current | Limited Availability | Manufacturing | 19/12/2024 |
| lorazepam | Tablet | 2.5 mg | Resolved | Available | Manufacturing | 19/12/2024 |
| tenofovir disoproxil succinate~emtricitabine | Tablet, film coated | 300.6 mg~200 mg | Current | Unavailable | Manufacturing | 19/12/2024 |
| rosuvastatin calcium | Tablet, film coated | 20.84 mg | Current | Limited Availability | Manufacturing | 19/12/2024 |
| dosulepin (dothiepin) hydrochloride | Capsule, hard | 25 mg | Current | Unavailable | Manufacturing | 19/12/2024 |
| cefaclor monohydrate | Oral Liquid, powder for | 52.45 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 19/12/2024 |
| dostarlimab | Injection, intravenous infusion | 500 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 19/12/2024 |
| cisplatin | Injection, solution | 1 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 19/12/2024 |
| citalopram hydrobromide | Tablet, film coated | 24.98 mg | Anticipated | Available | Manufacturing | 19/12/2024 |
| pravastatin sodium | Tablet, uncoated | 40 mg | Current | Unavailable | Manufacturing | 19/12/2024 |
| clarithromycin | Tablet, film coated | 250 mg | Current | Unavailable | Unexpected increase in consumer demand | 19/12/2024 |
| moclobemide | Tablet, film coated | 150 mg | Resolved | Available | Manufacturing | 19/12/2024 |
| bupivacaine hydrochloride monohydrate | Injection, solution | 52.7 mg | Current | Unavailable | Unexpected increase in consumer demand | 18/12/2024 |
| sildenafil citrate | Tablet, film coated | 28.09 mg | Current | Unavailable | Unexpected increase in consumer demand | 18/12/2024 |
| sumatriptan succinate | Tablet, film coated | 140 mg | Current | Unavailable | Manufacturing | 18/12/2024 |
| tranexamic acid | Injection, solution | 1000 mg | Anticipated | Available | Manufacturing | 18/12/2024 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 18/12/2024 |
| efmoroctocog alfa | Injection, powder for | 250 IU | Resolved | Available | Unexpected increase in consumer demand | 18/12/2024 |
| paroxetine hydrochloride | Tablet, film coated | 22.21 mg | Anticipated | Available | Manufacturing | 18/12/2024 |
| buprenorphine | Drug delivery system, transdermal | 5 mg | Current | Limited Availability | Manufacturing | 18/12/2024 |
| mesalazine | Tablet, enteric coated | 800 mg | Anticipated | Available | Manufacturing | 18/12/2024 |
| mesalazine | Tablet, enteric coated | 1.6 g | Anticipated | Available | Manufacturing | 18/12/2024 |
| Fremanezumab | Injection, solution | 225 mg | Current | Limited Availability | Unexpected increase in consumer demand | 18/12/2024 |
| clonazepam | Tablet, uncoated | .5 mg | Resolved | Available | Manufacturing | 18/12/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 1.54 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 18/12/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | .77 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 18/12/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 3.09 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 18/12/2024 |
| estradiol hemihydrate | Drug delivery system, transdermal | 2.32 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 18/12/2024 |
| methylphenidate hydrochloride | Capsule, modified release | 30 mg | Anticipated | Available | Manufacturing | 18/12/2024 |
| terbinafine hydrochloride | Tablet, uncoated | 281.3 mg | Resolved | Available | Manufacturing | 17/12/2024 |
| isosorbide dinitrate | Tablet, uncoated | 5 mg | Resolved | Available | Manufacturing | 17/12/2024 |
| fluorouracil | Injection, solution | 5000 mg | Anticipated | Available | Unexpected increase in consumer demand | 17/12/2024 |
| acetylcysteine | Injection, concentrated | 2 g | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 17/12/2024 |
| olmesartan medoxomil~amlodipine besilate~hydrochlorothiazide | Tablet | 40 mg~6.944 mg~25 mg | Current | Limited Availability | Manufacturing | 17/12/2024 |
| duloxetine hydrochloride | Capsule, enteric | 67.3 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 17/12/2024 |
| quetiapine fumarate | Tablet, film coated | 28.78 mg | Current | Unavailable | Manufacturing | 17/12/2024 |
| midazolam | Injection, solution | 5 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 17/12/2024 |
| midazolam | Injection, solution | 5 mg | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 17/12/2024 |
| rizatriptan benzoate | Tablet, orally disintegrating | 14.53 mg | Current | Limited Availability | Manufacturing | 17/12/2024 |
| prilocaine hydrochloride~felypressin | Injection, solution | 30 mg/mL~.54 microgram/mL | Anticipated | Available | Manufacturing | 17/12/2024 |
| temozolomide | Capsule, hard | 5 mg | Resolved | Available | Manufacturing | 17/12/2024 |
| temozolomide | Capsule, hard | 20 mg | Resolved | Available | Manufacturing | 17/12/2024 |
| temozolomide | Capsule, hard | 100 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 17/12/2024 |
| rosuvastatin calcium | Tablet, film coated | 10.42 mg | Resolved | Available | Manufacturing | 17/12/2024 |
| citalopram hydrobromide | Tablet, film coated | 49.98 mg | Current | Limited Availability | Manufacturing | 17/12/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 17/12/2024 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Unavailable | Unexpected increase in consumer demand | 17/12/2024 |
| gemeprost | Pessary | 1 mg | Discontinued | Reduction in supply until supply is exhausted | Manufacturing | 17/12/2024 |
| tenofovir disoproxil fumarate~emtricitabine | Tablet, film coated | 300 mg~200 mg | Anticipated | Available | Manufacturing | 17/12/2024 |
| fluorouracil | Injection, solution | 50 mg/mL | Current | Limited Availability | Manufacturing | 17/12/2024 |
| betahistine dihydrochloride | Tablet, uncoated | 16 mg | Resolved | Available | Manufacturing | 17/12/2024 |
| timolol maleate | Eye Drops, solution | 6.83 mg/mL | Current | Unavailable | Commercial Changes / Commercial viability | 17/12/2024 |
| lacosamide | Tablet, film coated | 50 mg | Resolved | Available | Manufacturing | 17/12/2024 |
| pregabalin | Capsule, hard | 25 mg | Current | Limited Availability | Manufacturing | 17/12/2024 |
| Semaglutide | Injection, solution | 1.34 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 17/12/2024 |
| Semaglutide | Injection, solution | 1.34 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 17/12/2024 |
| olanzapine | Tablet, uncoated | 2.5 mg | Current | Unavailable | Manufacturing | 17/12/2024 |
| methotrexate | Tablet | 2.5 mg | Anticipated | Available | Manufacturing | 17/12/2024 |
| timolol maleate | Eye Drops, solution | 6.84 mg/mL | Current | Unavailable | Manufacturing | 17/12/2024 |
| dorzolamide hydrochloride | Eye Drops, solution | 22.26 mg/mL | Current | Unavailable | Manufacturing | 17/12/2024 |
| clindamycin phosphate | Lotion | 10 mg/mL | Current | Unavailable | Manufacturing | 17/12/2024 |
| famotidine | Tablet, film coated | 20 mg | Current | Unavailable | Manufacturing | 17/12/2024 |
| methylphenidate hydrochloride | Tablet, modified release | 36 mg | Current | Limited Availability | Manufacturing | 17/12/2024 |
| risperidone | Tablet, film coated | 2 mg | Current | Limited Availability | Unexpected increase in consumer demand | 16/12/2024 |
| carboplatin | Injection, solution | 450 mg | Current | Limited Availability | Manufacturing | 16/12/2024 |
| bosentan monohydrate | Tablet, film coated | 129.08 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 16/12/2024 |
| mesalazine | Tablet, enteric coated | 250 mg | Anticipated | Available | Manufacturing | 16/12/2024 |
| rasagiline mesilate | Tablet | 1.56 mg | Resolved | Available | Manufacturing | 16/12/2024 |
| lacosamide | Tablet, film coated | 150 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 16/12/2024 |
| isavuconazonium sulfate | Capsule | 186.3 mg | Resolved | Available | Unexpected increase in consumer demand | 16/12/2024 |
| furosemide | Injection, solution | 10 mg/mL | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 16/12/2024 |
| thiotepa | Injection, powder for | 15 mg | Current | Limited Availability | Unexpected increase in consumer demand | 16/12/2024 |
| levothyroxine sodium | Tablet | 50 microgram | Current | Unavailable | Manufacturing | 16/12/2024 |
| nizatidine | Capsule | 150 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 16/12/2024 |
| nizatidine | Capsule | 300 mg | Current | Limited Availability | Manufacturing | 16/12/2024 |
2024年12月23日